Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Novartis Investigative Site, Mátraháza

Novartis Investigative Site, Roeselare

Novartis Investigative Site, Sint-Niklaas

Novartis Investigative Site, Orbassano

Novartis Investigative Site, George Town

Novartis Investigative Site, Bangkok

Novartis Investigative Site, Athens

Novartis Investigative Site, Marseille

Novartis Investigative Site, Rozzano

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Diyarbakır

Novartis Investigative Site, Oldenburg

Novartis Investigative Site, Madrid

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Istanbul

Novartis Investigative Site, Saint-Herblain

Novartis Investigative Site, Strasbourg

Novartis Investigative Site, Bron

Novartis Investigative Site, Bari

Novartis Investigative Site, Tübingen

Novartis Investigative Site, Kempten

Novartis Investigative Site, Kuching

Novartis Investigative Site, Beijing

Novartis Investigative Site, Varanasi

Novartis Investigative Site, Changsha

Novartis Investigative Site, Wuhan

Novartis Investigative Site, Thellakom Kottayam

The Brown University Oncology Group, Providence

Novartis Investigative Site, Pilar

Novartis Investigative Site, Buenos Aires

Novartis Investigative Site, Córdoba

Novartis Investigative Site, Córdoba

Novartis Investigative Site, Feldkirch

Novartis Investigative Site, Wels

Novartis Investigative Site, Salvador

Novartis Investigative Site, Belo Horizonte

Novartis Investigative Site, Halle

Novartis Investigative Site, Roma

Novartis Investigative Site, Breda

Novartis Investigative Site, Leeuwarden

Novartis Investigative Site, Porto

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Ankara

Novartis Investigative Site, Torquay